Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Eastman Chemical To Be Aided By Cost Actions, Acquisitions

Published 06/06/2018, 03:08 AM
Updated 07/09/2023, 06:31 AM

We issued an updated research report on Eastman Chemical Company (NYSE:EMN) on Jun 5.

Eastman Chemical’s shares have moved up 32.5% over a year, substantially outperforming 10.4% growth of the industry it belongs to.



Eastman Chemical’s high margin products and its aggressive cost management actions are likely to boost its earnings. Eastman Chemical saw higher profits in the first quarter, aided by strong growth in its specialty businesses and cost-control actions.

The company, in April, raised its earnings growth expectations for 2018 based on strong first-quarter results. It now expects adjusted earnings per share growth for 2018 to be 10-14% year over year, up from its prior view of 8-12%.

The company is focused on cost-cutting and productivity actions and increasing selling prices of its products, which are helping it to offset raw material cost inflation and other cost headwinds. It expects to realize $100 million of cost savings in 2018 under its cost-reduction program.

Eastman Chemical is also expected to gain from strategic acquisitions, especially of Taminco Corporation. The buyout has strengthened the company’s foothold in promising niche end-markets including food, feed and agriculture. The acquisition has also provided attractive cost- and revenue-synergy opportunities.

Further, the company is committed to reduce debt and boost shareholder returns leveraging strong free cash flow. The company repaid $350 million of debt last year. Moreover, it returned more than $180 million to shareholders during the first quarter of 2018 leveraging healthy free cash flow. Eastman Chemical expects to deliver strong earnings growth and generate solid free cash flow of more than $1.1 billion in 2018.

However, the company is exposed to volatility in ethylene prices which is weighing on its margins. Eastman Chemical is seeing a spike in raw material costs, which is anticipated to persist in the second quarter of 2018. The company expects raw material and energy prices, especially for olefins, to be volatile through 2018.

The company also faces cost headwinds associated with maintenance turnaround and start-up of new production facilities in 2018. It expects higher schedule maintenance cost in 2018.

Eastman Chemical Company Price and Consensus

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Zacks Rank & Stocks to Consider

Eastman Chemical currently carries a Zacks Rank #3 (Hold).

Some better-ranked companies in the basic materials space are FMC Corp. (NYSE:FMC) , Celanese Corp. (NYSE:CE) and The Chemours Company (NYSE:CC) . All three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

FMC Corp has an expected long-term earnings growth rate of 16.4%. Its shares have gained around 16.1% over a year.

Celanese has an expected long-term earnings growth rate of 8.9%. Its shares have moved up around 30.7% over a year.

Chemours has an expected long-term earnings growth rate of 15.5%. Its shares have gained around 27.2% over a year.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>



Eastman Chemical Company (EMN): Free Stock Analysis Report

Celanese Corporation (CE): Free Stock Analysis Report

FMC Corporation (FMC): Free Stock Analysis Report

Chemours Company (The) (CC): Free Stock Analysis Report
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.